GC Green Cross Holds Researcher-Led Symposium on Rozetel and Rozetelfin

Sharing Interim Research Results... Efficacy Demonstrated

GC Green Cross announced on the 29th that it held a researcher-led symposium on July 26-27 at the Parnas Hotel in Gangnam-gu, Seoul, focusing on the clinical usefulness of "Rozetel" and "Rozetelfin."

Researcher-led symposium on the clinical utility of Rosetel and Rosetelpine held by GC Green Cross on the 26th and 27th at Parnas Hotel, Gangnam-gu, Seoul. GC Green Cross

At this symposium, the latest evidence and practical applications of the "multi-drug combination" strategy, which treats both hypertension and dyslipidemia with a single formulation, were shared. The event was attended by approximately 100 healthcare professionals, including those from general hospitals and private clinics nationwide.

During the event, interim results from an observational study on "Rozetel" involving about 1,800 patients were presented. The study administered "Rozetel" to patients undergoing concomitant treatment for hypertension and dyslipidemia after percutaneous coronary intervention (PCI), and evaluated its efficacy and safety at 24 and 48 weeks.

The interim analysis showed a clear result: at 24 weeks, the proportion of patients who met both blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) targets improved by approximately 27% compared to before treatment. Separate analyses of each indicator also demonstrated an increasing trend in target achievement rates for both, supporting the clinical value of the combination therapy strategy for heterogeneous diseases.

Additionally, real-world treatment cases for various patient groups were shared, leading to further discussion on the clinical usefulness of "Rozetel" and "Rozetelfin" and the potential for expanding the target patient population.

Namgoong Hyun, Head of Domestic Sales at GC Green Cross, stated, "This symposium was a meaningful opportunity to confirm the effectiveness of combination therapy strategies in actual clinical practice," and added, "We will continue to accumulate diverse clinical data to provide more treatment options for healthcare professionals."